These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 16827283)

  • 1. [Experience in coenzyme Q10 application in complex therapy of coronary heart disease with dyslipidemia].
    Belaia OL; Kalmykova VI; Ivanova LA; Kochergina LG
    Klin Med (Mosk); 2006; 84(5):59-62. PubMed ID: 16827283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The influence of the bioflanoid dicvertin on the antioxidative system ceruloplasmin-transferrin and lipid peroxidation in patients suffering from stable coronary heart disease with dyslipidemia].
    Belaia OL; Fomina IG; Baĭder LM; Kuropteva ZV; Tiukavkina NA
    Klin Med (Mosk); 2006; 84(7):46-50. PubMed ID: 16924801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of coronary atherosclerosis by the use of combination therapy with antioxidant coenzyme Q10 and statins.
    Chapidze G; Kapanadze S; Dolidze N; Bachutashvili Z; Latsabidze N
    Georgian Med News; 2005 Jan; (118):20-5. PubMed ID: 15821319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis.
    Petrella RJ; Merikle E; Jones J
    Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
    Maciejewski S; Hilleman D
    Pharmacotherapy; 2008 May; 28(5):570-5. PubMed ID: 18447655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correction of antioxidative state during statin therapy of coronary heart disease with dyslipidemia].
    Artamoshina NE; Belaia OL; Radzevich AE; Kuropteva ZV; Baĭder LM
    Klin Med (Mosk); 2009; 87(11):25-9. PubMed ID: 20143561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of dyslipidemia and general ineffectiveness of its treatment in both primary and secondary prevention of coronary heart disease within family medicine framework--results of LIPIDOGRAM 2005--a nationwide epidemiological study. Dyslipidemia in Poland--ineffective treatment.
    Konduracka E; Jóźwiak J; Mastej M; Lukas W; Tykarski A; Szczepaniak-Chicheł L; Piwowarska W
    Przegl Lek; 2008; 65(12):834-7. PubMed ID: 19441674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary heart disease and dyslipidemia: a cross-sectional evaluation of prevalence, current treatment, and clinical control in a large cohort of Spanish high-risk patients: the PRINCEPS study.
    de Rojas FD; De Frutos T; Ponte A; Chacón JM; Vitale GC;
    Prev Cardiol; 2009; 12(2):65-71. PubMed ID: 19476579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
    Mohiuddin SM; Pepine CJ; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
    Am Heart J; 2009 Jan; 157(1):195-203. PubMed ID: 19081418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease.
    Shults CW; Flint Beal M; Song D; Fontaine D
    Exp Neurol; 2004 Aug; 188(2):491-4. PubMed ID: 15246848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
    Terra SG; Francone OL; Contant CF; Gao X; Lewin AJ; Nguyen TT
    Am J Cardiol; 2008 Aug; 102(4):434-9. PubMed ID: 18678301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of long-term cardiac training on lipids concentration in patients with chronic heart ischemic disease treated with simvastatin].
    Kałka D; Sobieszczańska M; Kopka L; Marciniak W; Zawadzka-Bartczak E; Bak A; Popielewicz-Kautz A; Korzeniowska J; Janczak J; Adamus J
    Pol Merkur Lekarski; 2007 Feb; 22(128):101-6. PubMed ID: 17598652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of dyslipidemia in the emergency department: impact of cholesterol testing on subsequent therapy.
    Blomkalns AL; O'Connell EM; Eady CE; Lindsell CJ; Gibler WB
    Am Heart J; 2006 Dec; 152(6):1182-6. PubMed ID: 17161073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The antioxidant protection of the heart by coenzyme Q10 in stable stenocardia of effort].
    Kogan AKh; Syrkin AL; Drinitsina SV; Kokanova IV
    Patol Fiziol Eksp Ter; 1999; (4):16-9. PubMed ID: 10598457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of niacin and simvastatin combination therapy.
    Bays H
    Am J Cardiol; 2008 Apr; 101(8A):3B-8B. PubMed ID: 18375239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease.
    Fu R; Sun YM; Su Y; Wu Y; Luan Y
    Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):982-3. PubMed ID: 18430057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.